TickerFacts.

Evommune, Inc. (EVMN): Capital Expenditures

Annual figures by period end, from SEC filings.

$235.0K
Year ended 2025-12-31
$501.0K
Trailing 12 months to 2026-06-30
2024-12-31: $88.0K2025-12-31: $235.0K$235.0K
2024-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$235.0K+167.0%2026-03-05, From 2025-01-01
2024-12-31$88.0Kn/a2026-03-05, From 2024-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Evommune, Inc. (EVMN)2025-12-31$235.0K+167.0%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$3.37Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$1.0K-91.7%
CV Sciences, Inc. (CVSI)2025-12-31$109.0K+505.6%
Pyxis Oncology, Inc. (PYXS)2025-12-31$9.0K-96.2%
Prelude Therapeutics Inc (PRLD)2025-12-31$67.0K-91.2%
Arbutus Biopharma Corp (ABUS)2025-12-31$0-100.0%
Jaguar Health, Inc. (JAGX)2024-12-31$16.0Kn/a
Crescent Biopharma, Inc. (CBIO)2025-12-31$919.0Kn/m

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗